Interferon beta (IFNß) is a common treatment used for patients with relapsing-onset MS [2]; however there is a large percentage of patients in which the IFNß therapy fails to reduce the relapse rate and the disability progression [3]. This evidence concerns the gene IFNB1 and myeloid sarcoma.